PYC Therapeutics advances clinical trials for RP11 treatment

PYC Therapeutics (ASX: $PYC) announces further improvement in visual function for RP11 patients participating in the Single Ascending Dose (SAD) study. The company's drug candidate, VP-001, has shown promising results in improving retinal sensitivity and reducing scotomas in patients with Retinitis Pigmentosa type 11 (RP11).

Executive commentary on RP11 clinical trial progress

PYC's CEO, Dr. Rohan Hockings, expressed excitement about the progress, stating, 'It is exciting to see VP-001's ability to address the root cause of RP11 in 'retina in a dish' models now translating to improved visual function in RP11 patients.'

Summary of RP11 clinical trial update

PYC Therapeutics (ASX: $PYC) is making significant strides in the development of an investigational drug, VP-001, for the treatment of Retinitis Pigmentosa type 11 (RP11). The company has reported further improvement in visual function for RP11 patients participating in the clinical trials, demonstrating the potential of VP-001 to address the root cause of RP11 and improve retinal sensitivity. With upcoming data read-outs and a focus on establishing clinical 'proof of concept,' PYC aims to initiate a registrational study in 2025, paving the way for the commercial launch of this promising drug candidate.